**Summary:**


2. Child/Adolescent Immunization: Work group is attempting to provide tools to help providers with vaccine schedules.

3. Yellow Fever Vaccine: YF-VAX (Sanofi) is only yellow fever vaccine in the US; cost ($150-350). A motion was tabled to recommend on one YF without a booster. To be addressed at next meeting.

4. Influenza (Vote): Costs:

<table>
<thead>
<tr>
<th>Vaccine product</th>
<th>Price/dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>LAIV</td>
<td>LAIV: $22.70</td>
</tr>
<tr>
<td>IIIV (with indication for ≤8 years)</td>
<td>IIIV3: $7.65 – $14.81; IIIV4: $14.90 – $21.09</td>
</tr>
</tbody>
</table>

5. Human Papillomavirus (HPV) Vaccines (2 items were discussed by no vote)
   a. Investigational 9-valent HPV vaccine was discussed
   b. 2-dose schedules for bivalent and quadrivalent HPV vaccines

6. Vaccine Safety
   a. Simultaneous administration of TIV with PCV and/or DTaP vaccines may be associated with an increased risk for benign febrile seizures in young children.
   b. Getting recommended childhood vaccines during a single healthcare visit has important benefits.
c. On-time vaccinations keep children protected against many infectious diseases, and providing multiple vaccinations in a healthcare visit minimizes the number of healthcare visits that parents, caregivers, and children must make.

7. Adult Immunization
   a. Overall coverage remains far below HP2020 targets
      i. 90% for 65+ for pneumococcal vaccine
      ii. 60% for high risk 19-64 for pneumococcal vaccine
      iii. 30% for 60+ years for Zoster vaccine
      iv. 90% for Hep B vaccine for HCP
   b. Some improvement from 2011
      i. Modest increase for HPV (women 19-26), Tdap (19-64 year olds), and herpes zoster (>60 year olds) vaccines
      ii. No improvements for other vaccines

8. 13-valent pneumococcal conjugate vaccine (PCV13)
   The addition of one dose of PCV13 for adults appears to be less cost-effective than other vaccination interventions.

9. Measles Update

10. Meningococcal Vaccines
    Until a MenB vaccine is licensed in the United States, MenB vaccine and MenB vaccination campaigns may only be provided under a CDC-sponsored expanded access IND.

11. Pertussis
    All HCP are recommended a single dose of Tdap and routine Td booster every 10 years.
    Nationally reported Tdap coverage among HCP is 31.4% (NHIS, 2012).

Next ACIP meeting Oct. 29-30, 2014